Pegvaliase dose escalation to 80 mg daily may lead to efficacy in patients who do not exhibit an optimal response at lower doses

In 2018, pegvaliase was approved as the first enzyme substitution treatment for phenylketonuria (PKU) and is now the second medication available for PKU patients since the approval of sapropterin dihydrochloride in 2007. Historically, dietary management has been the mainstay of treatment for PKU. Wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Vucko, Erika R., Havens, Kirsten E., Baker, Joshua J., Burton, Barbara K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421444/
https://www.ncbi.nlm.nih.gov/pubmed/36046394
http://dx.doi.org/10.1016/j.ymgmr.2022.100905

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421444/
https://www.ncbi.nlm.nih.gov/pubmed/36046394
http://dx.doi.org/10.1016/j.ymgmr.2022.100905

Ejemplares similares